Highlights Nkarta, Inc.

Equities

NKTX

US65487U1088

Real-time Estimate Cboe BZX Other stock markets 14:35:54 2024-06-27 EDT			5-day change	1st Jan Change
5.68 ^USD	-4.86%		+6.52%	-14.55%

04:09pm	Nkarta Initiates Trial of Cell Therapy to Treat Lupus Nephritis; FDA Clears Second Application	MT
12:00pm	Nkarta, Inc. Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Nkarta, Inc. Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications	06:00am	CI
Nkarta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Nkarta Prices $240.1 Million Underwritten Offering	03-25	MT
North American Morning Briefing : Tech in Focus on -2-	03-25	DJ
Nkarta Trims Q4 Loss -- Shares Up After Hours	03-21	MT
Nkarta, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-21	CI
Nkarta, Inc. Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition	12-09	CI
Nkarta, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis	23-10-17	CI
Nkarta Shares Double on Partnership With Lupus Therapeutics for Cell Therapy to Treat Lupus, FDA Application Approval	23-10-17	MT
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis	23-10-17	CI
Nkarta, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Nkarta, Inc. Appoints Alyssa Levin as Chief Financial Officer	23-07-05	CI
Nkarta, Inc. Appoints Alyssa Levin as Chief Business Officer	23-07-05	CI
Nkarta, Inc. Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia	23-06-27	CI
Nkarta, Inc. to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma	23-05-11	CI
Nkarta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Nkarta, Inc. Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting	23-04-17	CI
Nkarta, Inc. Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma	22-12-05	CI
Nkarta, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Nkarta, Inc.

Equities

NKTX

US65487U1088

Highlights

Filters